Miconazole mucoadhesive tablets: A novel delivery system

José A. Vazquez, Jack D. Sobel

Research output: Contribution to journalReview articlepeer-review

32 Scopus citations


Oropharyngeal candidiasis (OPC) is among the most common opportunistic infections observed in persons infected with human immunodeficiency virus. A once-daily miconazole 50 mg mucoadhesive buccal tablet (MBT) is a novel delivery system with potent in vitro activity against many Candida species, including some that may be resistant to other azoles. MBT, although more expensive, offers an effective, safe, and well-tolerated topical treatment option for OPC that is administered as a convenient once-daily dose.

Original languageEnglish (US)
Pages (from-to)1480-1484
Number of pages5
JournalClinical Infectious Diseases
Issue number10
StatePublished - May 15 2012
Externally publishedYes

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Miconazole mucoadhesive tablets: A novel delivery system'. Together they form a unique fingerprint.

Cite this